Skip to main content
Equibles

MetLife Investment Management, LLC

Position in RAPP — Rapport Therapeutics, Inc.

CIK 1529735 Whippany, NJ
Back to RAPP Full portfolio

Position in RAPP

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$750,435
+$249,921 QoQ
Shares Held
18,009
+12.6% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#82
of 159 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RAPP Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MetLife Investment Management, LLC holds $433,929,439 across 249 Biotechnology names. RAPP ranks #100 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 HALO
Halozyme Therapeutics, Inc.
 402,605 $31,511,893
2 PRAX
Praxis Precision Medicines, Inc.
 90,543 $30,312,890
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 58,072 $28,846,104
4 FTRE
Fortrea Holdings Inc.
 1,362,169 $23,701,740
5 AXSM
Axsome Therapeutics, Inc.
 89,662 $21,946,567
6 IMNM
Immunome Inc.
 859,076 $18,203,820
7 REGN
Regeneron Pharmaceuticals, Inc.
 22,880 $14,266,595
8 CYTK
Cytokinetics Inc
 140,046 $11,930,518

All Filings in RAPP

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $750,435 18,009
2026-03-31 $500,514 15,996
2025-12-31 $485,318 15,996
2025-09-30 $322,631 10,863
2025-06-30 $123,512 10,863
2025-03-31 $108,955 10,863
2024-12-31 $101,295 5,710
2024-09-30 $116,940 5,710